Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Standard therapy more effective than diabetes drug in helping women with PCOS achieve pregnancy

Standard therapy more effective than diabetes drug in helping women with PCOS achieve pregnancy

February 08, 2007

Penn researchers show that new drugs aren't necessarily better

(PHILADELPHIA) - Metformin, a drug used to treat diabetes and once thought to have great promise in overcoming the infertility associated with polycystic ovary syndrome (PCOS), is less effective than the standard fertility drug treatment, clomiphene, according to researchers from the University of Pennsylvania School of Medicine and the National Institutes of Health Reproductive Medicine research network. This is the largest, most comprehensive effort yet to compare the two drugs in helping PCOS patients achieve successful pregnancy. The findings appear in the February 8th, 2007 issue of the New England Journal of Medicine.




"With this study, my colleagues and I recommend and support the use of clomiphene alone and NOT in combination with Metformin as a first-line therapy for infertility in women with PCOS," said Christos Coutifaris, MD, PhD, Director of the Division of Reproductive Endocrinology and Infertility and the principal investigator from Penn. "These results emphasize the need to test any new application rigorously, no matter how promising it may seem initially."

According to the study authors, women who took metformin ovulated more that the women who were given the standard treatment. Similarly, women in the combination therapy group ovulated more frequently than did the women in either the clomiphene-alone or the metformin-alone groups. However, as the current study revealed, an increase in ovulation did not result in more successful pregnancies and deliveries for either the metformin alone, or combination group.

"The bottom line here is that ovulation does not necessarily result in a successful pregnancy," said Coutifaris "The results suggest that an ovulation due to clomiphene is two times as likely to result in pregnancy compared to an ovulation caused by metformin."

PCOS affects seven to eight percent of women in the United States and may be the most common cause of female infertility. With PCOS, an excess of male hormones interfere with ovulation and cause the ovaries to enlarge and fill with cysts.

Women with PCOS frequently experience insulin resistance, a pre-diabetic condition in which higher-than-normal amounts of insulin are required to allow glucose to enter tissues. Earlier studies had shown that drugs such as metformin - which make the body more sensitive to insulin - could increase ovulation in PCOS patients. Similarly, several smaller studies had suggested that metformin, alone or when taken together with the drug clomiphene, could result in greater fertility rates for PCOS patients than could clomiphene alone. Clomiphene fosters ovulation by stimulating the release of hormones needed for ovulation to occur.

To conduct the study, the researchers randomly assigned 626 infertile women with PCOS to one of three groups. The first group received clomiphene and a placebo. The second group received metformin and a placebo, and the third group received both metformin and clomiphene. The women took the medication for up to six months. The researchers tested the women's levels of the hormone progesterone to gauge when the women were ovulating.

The researchers found that fewer women in the metformin only group had given birth than had women in either of the clomiphene groups. In the metformin only group, 15 out of 208 women had given birth, or 7.2 percent. In the clomiphene only group, 47 out of 209 women had given birth, or 22.5 percent. In the combined clomiphene-metformin group, 56 out of 209 women had given birth (26.8 percent). The difference in the number of births between the clomiphene only group and the combined clomiphene-metformin group was not statistically significant. The researchers also found that, compared to the other women in the study, obese women were less likely to conceive during the course of the study and less likely to ovulate in response to metformin.

The study authors also noted that while metformin alone did not improve the chances for pregnancy, it was useful for lowering the high blood testosterone levels that occur with PCOS.

University of Pennsylvania School of Medicine



Related Metformin Current Events and Metformin News Articles Metformin Current Events and Metformin News RSS Metformin Current Events and Metformin News RSS
A decade later, lifestyle changes or metformin still lower type 2 diabetes risk
Intensive lifestyle changes aimed at modest weight loss reduced the rate of developing type 2 diabetes by 34 percent compared with placebo in people at high risk for the disease, researchers conclude based on 10 years of data.

Diabetes drug kills cancer stem cells in combination treatment in mice
In a one-two punch, a familiar diabetes drug reduced tumors faster and prolonged remission in mice longer than chemotherapy alone by targeting cancer stem cells, Harvard Medical School researchers reported in the September 14 online first edition of Cancer Research, a journal of the American Association for Cancer Research.

UT Southwestern physicians bust myths about insulin
People diagnosed with type 2 diabetes often resist taking insulin because they fear gaining weight, developing low blood sugar and seeing their quality of life decline.

Pancreatic cancer risk decreased by one anti-diabetic therapy, increased by others
The antidiabetic medication metformin is associated with a reduced risk of pancreatic cancer in diabetics, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

M. D. Anderson study finds common diabetic therapy reduces risk of pancreatic cancer
Taking the most commonly-prescribed anti-diabetic drug, metformin, reduces an individual's risk of developing pancreatic cancer by 62 percent.

Benefit of glinides is not proven
The benefit of glinides in the treatment of type 2 diabetes is not scientifically proven. Nor do they perform better than other antidiabetics available in tablet form, such as metformin and sulfonylureas.

What is the relationship between hepatocellular carcinoma and type 2 diabetes mellitus?
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related deaths.

Death rates same for diabetes and heart disease patients receiving drug therapy or surgery
There is no difference in mortality among patients with type 2 diabetes and stable heart disease who received prompt bypass surgery or angioplasty compared to drug therapy alone, according to a landmark study focused exclusively on patients with both conditions.

Routine diabetes screenings could cut health-care costs
Screening adults for diabetes could result in significant cost-savings for health care systems compared to the costs of not screening individuals at all.

Common diabetes drug may 'revolutionize' cancer therapies
Researchers at McGill University and the University of Pennsylvania have discovered that a widely used anti-diabetic drug can boost the immune system and increase the potency of vaccines and cancer treatments.
More Metformin Current Events and Metformin News Articles
Metformin

Metformin
by Clifford Bailey (Author)

Metformin may play in important role in the future in helping to prevent the development of diabetes: it is a strong candidate therapy for delaying the onset of the disease and potentially as part of a treatment programme to correct features of the metabolic syndrome.

This book celebrates 50 years of research into metformin and its use in the treatment of diabetes.  Metformin is still the drug of choice for managing patients with type 2 diabetes and all new drugs are tested in comparison with this, the gold standard.  Comprising seven sections, addressing different aspects of research on metformin and its applications, this book is edited by a world class team of expert diabetologists and beautifully presented in two colour throughout.  It also includes a bibliography...

Beta Fast GXR Glucose Balance Bonus 180+30 Free

Beta Fast GXR Glucose Balance Bonus 180+30 Free
by Informulab

Beta Fast GXR Glucose Balance contains finest quality standardized extract Gymnema Sylvestre in standardized, concentrated, extended-release tablets. Clinically shown to promote natural glucose balance, with dosing of just two tablets per day.Extensively analyzed for safety, each batch undergoes a minimum of two inspections for quality and consistency. No other Gymnema supplement offers the extensive quality control of Beta Fast GXR Glucose Balance.

  Diabetes and metformin: A research and clinical update (International congress and symposium series)
by Royal Society of Medicine (Publisher)



Beta Fast GXR Glucose Tolerance 180ct

Beta Fast GXR Glucose Tolerance 180ct
by Informulab

BETA FAST GXR Glucose Tolerance contains concentrated, chemically analyzed, standardized Gymnema sylvestre extract (same as original Glucose Balance), 300mg, with two additional ingredients: Chromium Picolinate 200mcg to promote cellular insulin sensitivity and Vitamin C 100mg for improved absorption. Just two tablets per day provide the necessary dose to help you promote a natural glucose balance. Package contains a 3 month supply.

  A rational approach to type 2 diabetes in teens: metformin has to be considered the clear first-line agent for type 2 diabetes in teens; plus, it's approved.(Diabetes): ... An article from: Family Practice News
by Bruce Jancin (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on November 15, 2004. The length of the article is 1159 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: A rational approach to type 2 diabetes in teens: metformin has to be considered the clear first-line agent for type 2 diabetes in teens; plus, it's approved.(Diabetes)
Author: Bruce Jancin
Publication: Family Practice News (Magazine/Journal)
Date: November 15, 2004
Publisher: International Medical News Group
Volume: 34 Issue: 22 Page:...

  Metformin's PCOS benefits not limited to obese women: increases ovulation, reduces testosterone in those with normal insulin sensitivity. (Polycystic Ovary ... An article from: Internal Medicine News
by Timothy F. Kirn (Author)

This digital document is an article from Internal Medicine News, published by International Medical News Group on September 1, 2002. The length of the article is 476 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Metformin's PCOS benefits not limited to obese women: increases ovulation, reduces testosterone in those with normal insulin sensitivity. (Polycystic Ovary Syndrome).
Author: Timothy F. Kirn
Publication: Internal Medicine News (Magazine/Journal)
Date: September 1, 2002
Publisher: International Medical News Group
Volume: 35 Issue: 17 Page:...

Beta Fast GXR Glucose Balance 180ct

Beta Fast GXR Glucose Balance 180ct
by Informulab

Beta Fast GXR Glucose Balance contains finest quality standardized extract Gymnema Sylvestre in standardized, concentrated, extended-release tablets. Clinically shown to promote natural glucose balance, with dosing of just two tablets per day.Extensively analyzed for safety, each batch undergoes a minimum of two inspections for quality and consistency. No other Gymnema supplement offers the extensive quality control of Beta Fast GXR Glucose Balance.

  Consider metformin, insulin in type 2 diabetes.(Clinical Rounds): An article from: Pediatric News
by Bruce Jancin (Author)

This digital document is an article from Pediatric News, published by International Medical News Group on November 1, 2004. The length of the article is 1154 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Consider metformin, insulin in type 2 diabetes.(Clinical Rounds)
Author: Bruce Jancin
Publication: Pediatric News (Magazine/Journal)
Date: November 1, 2004
Publisher: International Medical News Group
Volume: 38 Issue: 11 Page: NA

Distributed by Thomson...

  Metformin Appears Effective in Teens With PCOS.(polycystic ovary syndrome)(Brief Article): An article from: Family Practice News
by Bruce Jancin (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on August 15, 2000. The length of the article is 657 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Metformin Appears Effective in Teens With PCOS.(polycystic ovary syndrome)(Brief Article)
Author: Bruce Jancin
Publication: Family Practice News (Magazine/Journal)
Date: August 15, 2000
Publisher: International Medical News Group
Volume: 30 Issue: 16 Page: 4

Article Type: Brief Article

Distributed by Thomson...

Beta Fast GXR Glucose Tolerance 60ct

Beta Fast GXR Glucose Tolerance 60ct
by Informulab

BETA FAST GXR Glucose Tolerance contains concentrated, chemically analyzed, standardized Gymnema sylvestre extract (same as original Glucose Balance), 300mg, with two additional ingredients: Chromium Picolinate 200mcg to promote cellular insulin sensitivity and Vitamin C 100mg for improved absorption. Just two tablets per day provide the necessary dose to help you promote a natural glucose balance.

© 2009 BrightSurf.com